移动站  | 2017年12月17日 星期日
用户登录

当前位置:首页 >> 师资队伍

基本信息:

姓名: 黄河
职务: 医学院党委书记,副院长;浙江大学血液病研究所所长;浙江大学医学院附属第一医院骨髓移植中心主任
职称: 教授
学历: 博士
专业: 内科学(血液病);干细胞与组织工程
所属院系: 浙医一院
研究方向: 造血干细胞移植与干细胞基础研究; 血液病临床与基础研究; CART等免疫细胞治疗
电话: 0571-88208003
信箱: hehuangyu@126.com
个人主页: http://person.zju.edu.cn/0093405

个人简介:

黄河,浙江大学求是特聘教授,973首席科学家,主任医师,博士生导师。现任浙江大学医学院党委书记、副院长,浙江大学血液病研究所所长,浙江大学医学院附属第一医院骨髓移植中心主任1984年起从事血液学、造血干细胞移植和干细胞基础与转化研究,先后于2003年及20152次荣获国家科技进步奖二等奖。

作为负责人承担973863,国家自然科学基金重点项目,国家自然科学基金国际合作与交流项目等26项。近10年在国内外学术期刊发表论文200余篇,其中在BloodLeukemiaSCI杂志发表论文130篇(其中通讯作者论文93篇)。获省部级以上奖项14项,授权发明专利16项。5年在国际大型会议担任主席、特邀报告和口头报告58次。作为大会主席分别于2005年和2014年在杭州主办亚太国际骨髓与造血干细胞移植大会。主编人民卫生出版社第一版和第二版全国研究生《血液内科学》教材,参编著作及教材5部。任国际造血干细胞移植领域权威杂志Bone Marrow TransplantationBiology of Blood and Marrow Transplantation Journal of hematology and oncology 编委。

 

研究方向:

造血干细胞移植与干细胞基础研究; 血液病临床与基础研究; CART等免疫细胞治疗


现任职务:

浙江大学医学院党委书记、副院长

浙江大学医学院附属第一医院骨髓移植中心主任

浙江大学血液病研究所所长

 

学习经历:

1979.9-1984.7 浙江医科大学         本科         学士        

1987.9-1990.7 浙江医科大学         研究生     硕士        

1990.9-1993.7 浙江医科大学         研究生     博士

 

工作经历:

1984.7-1987.9 浙江省金华市中心医院         住院医师

1993.7-1995.9 浙江大学医学院附属第一医院     助理研究员

1995.9-1997.9 浙江大学医学院附属第一医院     副研究员

1997.4-1997.10        德国基尔大学血液病理所     高级访问学者

1997.9-2000.9 浙江大学医学院附属第一医院血液科         副主任/副主任医师

1997.9-2016.10        浙江大学医学院血液病研究所     副所长

2016.10-至今      浙江大学医学院血液病研究所         所长

2000.9-至今    浙江大学医学院附属第一医院骨髓移植中心     主任/主任医师

2000.9-至今    浙江大学医学院     教授

2005.9-至今    浙江大学医学院     副院长

2012.5-至今    浙江大学医学院     党委书记

 

学术任职:

中华医学会血液学专业委员会造血干细胞应用学组,副组长

中华医学会血液学分会,常务委员

中国抗癌协会血液肿瘤专业委员会常务委员会,委员

亚太国际骨髓移植组织国际学术委员会常务委员会,委员

中华医学会浙江省分会血液专业委员会,主任委员

中国抗癌协会浙江省分会血液淋巴肿瘤专业委员会,主任委员

中华医学会浙江省分会,理事

中国免疫学会浙江省分会,常务理事

中华骨髓库专家委员会,副主任委员

中国病理生理学会实验血液学专业委员会,委员

中国免疫学会血液免疫分会,委员

中国生物医学工程学会干细胞工程技术分会,委员

国家重点研发计划“干细胞及转化研究”重点专项专家组成员

中国医师协会血液分会,常委

海峡两岸医药卫生交流协会血液病学专家委员会,副主任委员

美国血液学协会,会员

欧洲血液学协会,会员

国际慢性粒细胞白血病研究协会,委员

 

杂志编委:

Bone Marrow Transplantation

Journal of Hematology and Oncology

Biology of Blood and Marrow Transplantation

中华医学英文版

中华内科杂志

中华血液学杂志

白血病˙淋巴瘤

国际输血与血液学杂志

中华移植杂志

实用内科杂志

 

科技奖励:

1.  黄河,罗依,蔡真,王金福,肖浩文,施继敏,谭亚敏,林茂芳,来晓瑜,赵妍敏,异基因造血干细胞移植关键技术创新与推广应用,国务院,国家科学技术进步奖,二等奖,2015

2.  黄河,林茂芳,孟海涛,蔡真,金洁,严力行,钱文斌,胡晓蓉,金爱云,李黎,陈水云,谢万灼,何静松,罗依,黄健,叶琇锦,张洁,楼基余,孟筱坚,郑伟燕,非亲缘异基因骨髓移植临床研究,国务院,国家科学技术进步奖,二等奖,2003

3.  黄河,罗依,肖浩文,来晓瑜,谭亚敏,施继敏,蔡真,金爱云,胡晓蓉,陈水云,郑伟燕,朱园园,郑龑龙,胡永仙,吴功强,异基因造血干细胞移植重要并发症的预警与诊治新技术,教育部,高等学校科学技术进步奖,一等奖,2013

4.  蔡真,何静松,韩晓雁,易庆,施继敏,郑高锋,叶琇锦,谢万灼,林茂芳,黄河,罗依,孟筱坚,郑伟燕,多发性骨髓瘤危险度分层新模式的建立及应用研究,浙江省人民政府,浙江省科学技术奖,一等奖,2013

5.  蔡真,何静松,韩晓雁,易庆,施继敏,郑高锋,叶琇锦,谢万灼,林茂芳,黄河,罗依,孟筱坚,郑伟燕,多发性骨髓瘤危险度分层新模式的建立及应用研究,浙江省卫生厅,浙江省医药卫生科技创新奖,一等奖,2013

6.  黄河, 王金福, 马列, 高长有, 来晓瑜, (), 于晓虹, 郑强, 劳丽红, 沈建根, 赵海光, 蔡真, 李丹,间充质干细胞与组织工程产品的研发与应用,浙江省人民政府,浙江省科学技术奖,一等奖,2011

7.  黄河,王金福,高长友,马列,柴莹,来晓瑜,于晓红,郑强,劳丽红,沈建根,赵海光等18人,间充质干细胞与组织工程产品的研发与应用,浙江省卫生厅,浙江省医药卫生科技创新奖,一等奖,2011

8.  黄河,罗依,赵妍敏,施继敏,谭亚敏,来晓瑜,蔡真,林茂芳,吴功强,吴康妮,何静松,郑伟燕,叶琇锦,慢性粒细胞白血病分子靶向治疗及异基因造血干细胞移植最新策略的的建立与推广,浙江省人民政府,浙江省科学技术奖,一等奖,2010

9.  林茂芳,牟海波,黄河,蔡真,孟筱坚,俞静,郑伟燕,急性移植物抗宿主病防治的基础和临床研究,浙江省人民政府,浙江省科学技术奖,三等奖,2008

10.林茂芳,牟海波,黄河,蔡真,孟筱坚,俞静,郑伟燕,何静松,谢万灼等11人,急性移植物抗宿主病防治的基础和临床研究,浙江省卫生厅,浙江省医药卫生科技创新奖,二等奖,2008

11.王金福,黄河,潘志军,来晓瑜,罗依,王建安,解纯刚,人骨髓间充质干细胞纯化建系及临床试验研究,浙江省科学技术奖,三等奖,2007

12.蔡真,林茂芳,黄河,佟红艳,包悍英,施继敏,熊红,丁伟荣,薛军,骨髓增生异常综合征发病机理及临床研究,浙江省人民政府,浙江省科学技术奖,二等奖,2006

13.蔡真,林茂芳,黄河,佟红艳,包悍英,施继敏,熊红,丁伟荣,薛军等13人,骨髓增生异常综合征发病机理及临床研究,浙江省卫生厅,浙江省医药卫生科技创新奖,二等奖,2006

14.黄河,沈建根,来晓瑜,罗依,丁伟,梁彬,黄黎,人骨髓间充质干细胞特异性单克隆抗体的制备及应用,浙江省卫生厅,浙江省医药卫生科技创新奖,三等奖,2006

15.黄河,林茂芳,施继敏,孙洁,陈巧芳,楼基余,郑伟燕,丁伟,陈水云,人端粒结合因子(TRF1)的临床与基础研究,浙江省人民政府,浙江省科学技术奖,二等奖,2003年。

16.黄河,林茂芳,施继敏,孙洁,陈巧芳,楼基余,郑伟燕,丁伟,陈水云等12人,人端粒结合因子(TRF1)的临床与基础研究,浙江省卫生厅,浙江省医药卫生科技创新奖,二等奖,2003年。

17.黄河,林茂芳,孟海涛,蔡真,金洁,严力行,钱文斌,谢万灼,李黎,黄健,胡晓蓉,金爱云,陈水云,非亲缘异基因骨髓移植的临床研究,浙江省人民政府,浙江省科学技术奖,一等奖,2002年。

18.林茂芳,蔡真,麦文渊,谢万灼,黄河,萌小莉,叶秀锦,王云贵,张洁,高三尖杉酯碱致白血病细胞凋亡的信号传导和基因调控的研究及其临床意义,浙江省人民政府,浙江省科学技术奖,二等奖,2002年。

19.林茂芳,蔡真,麦文渊,谢万灼,黄河,萌小莉,叶秀锦,王云贵,张洁,周思文,林修基,高三尖杉酯碱致白血病细胞凋亡的信号传导和基因调控的研究及其临床意义,浙江省卫生厅,浙江省医药卫生科技创新奖,一等奖,2002年。

20.黄河,林茂芳,孟海涛,严力行,钱文斌,金洁,蔡真,谢万灼,李黎,黄健,胡晓蓉,非亲缘异基因骨髓移植的临床研究,浙江省卫生厅,浙江省医药卫生科技创新奖,一等奖,2001年。

21.钱文斌,黄河,孟海涛,严力行,金洁,李新杨,林茂芳,脐血CD34+造血干细胞纯化和体外扩增的研究,浙江省卫生厅,浙江省医药卫生科技创新奖,三等奖,2001年。

22.严力行,林茂芳,傅启华,黄河,朱俊等,血小板血型基础与临床综合研究,浙江省人民政府,浙江省科学技术进步奖,三等奖,2000年。

23.严力行,林茂芳,傅启华,黄河,朱俊,血小板血型基础与临床综合研究,浙江省卫生厅,浙江省医药卫生科技奖,二等奖,2000年。

24.黄河,陈巧芳,林茂芳,郑伟燕,傅剑云,陈水云,人端粒重复序列结合因子的克隆、表达纯化和多抗制备,浙江省卫生厅,浙江省医药卫生科技奖,二等奖,2000年。

25.林茂芳,黄河,麦文渊,林修基,钱文斌,程控冻存对人单个核细胞IL-1IL-2TNF影响的机理研究,浙江省人民政府,浙江省科学技术进步奖,三等奖,1999年。

26.林茂芳,黄河,麦文渊,林修基,钱文斌,孟海涛,梁毅,张丽娟,陈水云,程控冻存对人单个核细胞IL-1IL-2TNF影响的机理研究,浙江省卫生厅,浙江省医药卫生科技奖,二等奖,1999年。

 

主要承担科研项目:

1.    国家自然科学基金重点项目(81730008):CD44/CD49d介导骨髓微环境庇护和MIRL抵抗穿孔素/颗粒酶杀伤途径在CAR-T细胞治疗后急性淋巴细胞白血病CD19阳性复发中的作用和机制(2018-2022)(主持人)295

2.      国家自然科学基金国际合作与交流项目(81520108002):WAS-iPSCs突变基因通过CRISPR/Cas9靶向修复并向造血细胞定向分化研究(2016-2020)(主持人)282

3.      国家重点基础研究发展计划(973项目)(2015CB964900): 多能干细胞定向分化为造血干细胞的调控机理及功能研究(2015-2019)(主持人), 689

4.      国家自然科学基金重点项目(81230014):PTPN21基因突变和以NKG2D为核心的免疫网络失衡在急性淋巴细胞白血病异基因造血干细胞移植后复发中的作用与机制研究 (2012-2017) (主持人),270

5.      国家自然科学基金面上项目(81170501):CEBPA单基因多点突变致急性白血病发生及其分子机制研究 2012-2015)(主持人),65

6.      浙江省重大科技专项重点社会发展项目(2012C13021-1):难治、复发白血病新分子靶标的发现及综合治疗技术的建立(2012-2015)(主持人),100

7.      国家高技术研究发展计划(863计划)子课题(2011AA020117: 骨髓间充质干细胞新药的研究开发 (2011-2014) (主持人),180

8.      浙江省自然科学基金重点项目(Z2100097):调控ALT相关PML小体形成蛋白质作用网络的研究(2011-2014)(主持人),40

9.      高等学校博士学科点专项科研博导类基金(20100101110121):人iPS细胞体外向红细胞诱导分化及其生物学特性的研究(2011-2013)(主持人),8

10.   卫生部科学研究基金(WKJ2011-2-001):间充质干细胞体内动员及富集分选平台技术的创建 2011-2013)(主持人),15

11.   国家自然科学基金(30871098)PML3蛋白及其SUMO化修饰在ALT永生化细胞中的功能及分子机制的研究(2009-2011)(主持人),32

12.   国家自然科学基金(30770919):一个新的中心体蛋白TACP1在细胞有丝分裂中的功能及分子机制研究(2008-2010)(主持人)30

13.   浙江省医学重点学科:干细胞与组织工程学(2012-2014)(负责人)

14.   浙江省医学重点学科:医学组织工程学(2008-2010)(负责人)

15.   卫生部行业基金(200802027):血液恶性肿瘤及造血干细胞移植患者侵袭性真菌感染的早期抗原和分子生物学诊断实验研究(2008-2011)(子课题负责人) 20

16.   浙江省科技厅重大研究计划(2006C13022):基于干细胞技术的组织工程研究和产品开发(2007-2009)(主持人)100

17.   国家自然科学基金(30570941):一个新的TRF1 结合蛋白TRF1BP1 的功能及对细胞周期调控机制的研究(2006-2007)(主持人)8

18.   (WKJ2005-2-036):自体造血干细胞联合非清髓异基因造血干细胞移植治疗多发性骨髓瘤临床研究(2005-2007)(主持人)30

19.   浙江省自然科学基金(R204232):浙江省自然科学基金青年科技人才培养项目: NK细胞抑制性KIR功能修饰对移植物抗宿主病的影响及机理研究-黄河课题组(2005-2007)(主持人)25

20.   国家重点基础规划发展项目973项目子课题(2002CB713704):调控细胞增殖与肿瘤细胞转移重要蛋白质作用网络研究(20032007)(主持人)102

21.   浙江省科技厅重点科研项目(2003C23015):间充质干细胞纯化建系和临床应用(2003-2005)(主持人)20

22.   浙江省九五科技攻关重大项目(001103058):非亲缘异基因骨髓移植临床研究(2000-2003)(主持人)50

23.   浙江省医药卫生九五攻关重点项目(2000ZD001):预防非亲缘异基因骨髓移植中急性移植物抗宿主病的临床和实验研究(2000-2002)(主持人)10

24.   浙江省自然科学基金(399141):急性髓细胞性白血病Tankyrase的表达研究 (2000-2002)(主持人)4

25.   国家自然科学基金(39870339):急性髓细胞性白血病与人端粒重复序列结合因子(TRF1)突变和表达的研究(1999-2001)(主持人)13

26.   浙江省科技厅(991103181):人端粒重复序列结合因子单抗制备及检测技术(1999-2000)(主持人)3

 

发表论文:

1.       Lin Y, Wang B, Shan W, Tan Y, Feng J, Xu L, Wang L, Han B, Zhang M, Yu J, Yu X, Huang H*. mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation. Clin Immunol. 2017 Nov 10. 

2.       Wang J, Hu Y, Huang H*. Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. J Leukoc Biol. 2017 Dec;102(6):1347-1356

3.       Wei G, Wang J, Huang H, Zhao Y. Novel immunotherapies foradult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol.2017 Aug 18;10(1):150.

4.       Zhao Y, Wang J, Luo Y, Shi J, Zheng W,Tan Y, Cai Z, Huang H*. Reduced-intensityallogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinibtreatment in young patients with chronic myeloid leukemia. Ann Hematol. 2017Aug;96(8):1353-1360.

5.       Liu S, Ye Z, Gao Y, He C, Williams DW, Moliterno A, Spivak J, Huang H*, ChengL.Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene. Stem Cell Res. 2017 Jan;18:57-59.

6.       Santoro N, Ruggeri A, Labopin M,Bacigalupo A, Ciceri F, Gülbaş Z, Huang H, Afanasyev B, Arcese W, Wu D, Koc Y,Tischer J, Santarone S, Giebel S, Mohty M, Nagler A. Unmanipulatedhaploidentical stem cell transplantation in adults with acute lymphoblasticleukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.JHematol Oncol. 2017;10(1):113. 

7.       Yu J, Hu Y, Pu C, Liang Z, Cui Q,Zhang H, Luo Y, Shi J, Jin A, Xiao L, Wu Z, Huang H*.Successfulchimeric Ag receptor modified T cell therapy for isolated testicular relapseafter hematopoietic cell transplantation in an acute lymphoblastic leukemia patient.BoneMarrow Transplant. 2017 Jul;52(7):1065-1067.

8.       Wei G, Ding L, Wang J, Hu Y, Huang H*. Advances of CD19-directed chimericantigen receptor-modified T cells in refractory/relapsed acute lymphoblasticleukemia. Exp Hematol Oncol. 2017 Apr14;6:10. 

9.       Lai R, Gu M, Jiang W, Lin W, Xu P, LiuZ, Huang H, An H, Wang X*.Raf Kinase Inhibitor Protein Preferentially Promotes TLR3-Triggered Signaling and Inflammation. J Immunol.2017 May 15;198(10):4086-4095. 

10.   Tan Y, Xiao H, Wu D, Luo Y, Lan J, LiuQ, Yu K, Shi J, He J, Zheng W, Lai X, Zhu Y, Du K, Ye Y, Zhao Y, Zheng G, Hu Y,Han X, Zheng Y, Wei G, Cai Z, Huang H*. Oncoimmunology. Combining therapeutic antibodiesusing basiliximab and etanercept for severe steroid-refractory acutegraft-versus-host disease: A multi-center prospective study. 2017 Jan6;6(3):e1277307. 

11.   Han B, Zhao Y, Lin Y, Fu S, Wang L,Zhang M, Tie R, Wang B, Luo Y, Liu L, Yu J, Huang H*.Hydroxychloroquine sensitizes chronicmyeloid leukemia cells to Vγ9Vδ2 T cell-mediated lysis independent ofautophagy. Int J Oncol. 2017May;50(5):1810-1820.

12.   Tie R, Zhang T, Yang B, Fu H, Han B,Yu J, Tan Y, Huang H*. Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis. Oncotarget.2017 Apr 18;8(16):27645-27660. 

13.   Piemontese S, Ciceri F, Labopin M,Arcese W, Kyrcz-Krzemien S, Santarone S, Huang H, Beelen D, Gorin NC, Craddock C,Gulbas Z, Bacigalupo A, Mohty M, Nagler A. A comparison between allogeneic stemcell transplantation from unmanipulated haploidentical and unrelated donors inacute leukemia.J Hematol Oncol. 2017 Jan 19;10(1):24.

14.   Han X, Wang L, Shi H, Zheng G, He J,Wu W, Shi J, Wei G, Zheng W, Sun J, Huang H, Cai Z*. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathyin patients with multiple myeloma. BMC Cancer. 2017 Jan 9;17(1):40. 

15.   Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C,Liang Z, Wei G, Cui Q, Sun J, Jiang J, Xie J, Tan Y, Ni W, Tu J, Wang J, Jin A,Zhang H, Cai Z, Xiao L, Huang H*. Potent Anti-leukemia Activities ofChimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patientswith Relapsed/Refractory Acute Lymphocytic Leukemia. Clin Cancer Res. 2017 Jul1;23(13):3297-3306.

16.   Wang Y, Wang Y, Chang T, Huang H*, Yee JK. Integration-defectivelentiviral vector mediates efficient gene editing through homology-directedrepair in human embryonic stem cells. Nucleic Acids Res. 2017 Mar 17;45(5):e29.

17.   Hu Y, Cui Q, Ye Y, Luo Y, Tan Y, ShiJ,  Huang H*. Reduction ofFoxp3+ T cell subsets involved in incidence of chronic graft-versus-hostdisease after allogeneic hematopoietic stem cell transplantation.HematolOncol.2017 Mar;35(1):118-124. 

18.   Gu M, Liu Z, Lai R, Liu S, Lin W,Ouyang C, Ye S, Huang H, Wang X*. RKIPand TBK1 form a positive feedback loop to promote type I interferon productionin innate immunity. EMBO J. 2016 Dec 1;35(23):2553-2565.

19.   Zhang M, Fu H, Lai X, Tan Y, Zheng W,Shi J, Zhao Y, Lin M, He J, Cai Z, Luo Y, Huang H*. Minimal Residual Disease at FirstAchievement of Complete Remission Predicts Outcome in Adult Patients withPhiladelphia Chromosome-Negative Acute Lymphoblastic Leukemia. PLoS One. 2016Oct 3;11(10):e0163599.

20.   Sun J, Hu J, Huang Y, Ying SW, Han XY, Zheng YL,  Huang H*. Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.Chin Med J (Engl). 2016 Oct 20; 129 (20): 2512-2513. 

21.   Xu Y, Shan W, Li X, Wang B, Liu S,Wang Y, Long Y, Tie R, Wang L, Cai S, Zhang H, Lin Y, Zhang M, Zheng W, Luo Y,Yu X, Yee JK, Ji J, Huang H*. A syntheticthree-dimensional niche system facilitates generation of functional hematopoietic cells from human-induced pluripotent stem cells. J Hematol Oncol.2016 Sep 29;9(1):102.

22.   Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C,Liang B, Luo Y, Shi J, Jin A, Xiao L, Huang H*. Predominant cerebral cytokine releasesyndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. JHematol Oncol. 2016 Aug 15;9(1):70. 

23.   Zhu N, Wang H, Wei J, Wang B, Shan W,Lai X, Zhao Y, Yu J, Huang H*. NR2F2regulates bone marrow-derived mesenchymal stem cell-promoted proliferation ofReh cells. Mol Med Rep. 2016 Aug;14(2):1351-6. 

24.   Liu L, Yu Q, Hu K, Wang B, Zhang Y, XuY, Fu S, Yu X, Huang H*. Electro Acupuncture Promotes Endogenous Multipotential Mesenchymal Stem Cell Mobilization into the Peripheral Blood. Cell PhysiolBiochem. 2016;38(4):1605-17.

25.   Luo C, Wang J, Hu Y, Luo Y, Tan Y, JinA, Wei B, Hu H, Huang H*.Cunning hamella bertholletiae Infection in a HLA-Haploidentical Hematopoietic Stem Cell Transplant Recipient with Graft Failure: Case Report and Review ofthe Literature.Mycopathologia. 2016 Oct;181(9-10):753-8.

26.   Ye Y, Zheng W, Wang J, Hu Y, Luo Y,Tan Y, Shi J, Zhang M, Huang H*. Risk and prognostic factors oftransplantation-associated thrombotic microangiopathy in allogeneichaematopoietic stem cell transplantation: a nested case control study. HematolOncol. 2016 Jun 1. 

27.   Wu WJ, Dong MM, Chen Y, He JS, Huang H, Cai Z*.Acute myeloid leukemia of a primary hepatic carcinoma patient after liver transplantation: a case reportand literature review. Int J Clin Exp Pathol. 2015 .8(10):13655-60.

28.   26. Zhu N, Wang H, Wang B, Wei J, Shan W,Feng J, Huang H*.A Member ofthe Nuclear Receptor Superfamily, Designated as NR2F2, Supports theSelf-Renewal Capacity and Pluripotency of Human Bone Marrow-Derived MesenchymalStem Cells. Stem Cells Int. 2016:5687589. 

29.   Lin W, Ma C, Su F, Jiang Y, Lai R,Zhang T, Sun K, Fan L, Cai Z, Li Z, Huang H, Li J, Wang X*. Raf kinase inhibitorprotein mediates intestinal epithelial cell apoptosis and promotes IBDs inhumans and mice.Gut. 2016 Jan 22. 

30.   Zhou M, Zheng Y, Ma S, Zhou, Li L, ZhuJ, Zhu L, Yang X, Luo Y, Huang H, Ye X, Xie W*. Clinical observationon hemogram variation of allogeneic donors from Chinese population forperipheral hematopoietic stem cells collection.Stem Cells Dev. 2016.25(10):798-802.

31.   Hu Y, Cui Q, Luo C, Luo Y, ShiJ,  Huang H*. A promisings word of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.Blood Rev. 2016.30(3):179-188. 

32.   Xiao H, Wang LM, Luo Y, Lai X, Li C,Shi J, Tan Y, Fu S, Wang Y, Zhu N, He J, Zheng W, Yu X, Cai Z,  Huang H*.  Mutations in epigenetic regulators areinvolved in acute lymphoblastic leukemia relapse following allogeneichematopoietic cell transplantation. Oncotarget. 2016. 7(3):2696-708. 

33.   Long Y,  HuangH*. On signalingpathways: hematopoietic stem cell specification from hemogenic endothelium. SciChina Life Sci. 2015.58(12):1256-61.

34.   Wang L, Xiao H, Zhang X, Liao W, Fu S, Huang H*.  Restoration of CCAAT enhancer binding proteinα P42 induces myeloid differentiation and overcomes all-trans retinoic acidresistance in human acute promyelocytic leukemia NB4-R1 cells. Int J Oncol.2015 Nov;47(5):1685-95.

35.   Zheng FL, Shi JM, Hu YX, Zheng YL, CaiZ, Huang H*. The first casereport of a patient with simultaneous haemophilia A and accelerated phasechronic myelogenous leukaemia. Haemophilia. 2015 Nov;21(6):e507-10.

36.   Shi JM, Pei XY, Luo Y, Tan YM, Tie RX,He JS, Zheng WY, Zhang J, Cai Z, Lin MF,  HuangH*.. Invasivefungal infection in allogeneic hematopoietic stem cell transplant recipients:single center experiences of 12 years.J Zhejiang Univ Sci B. 2015Sep;16(9):796-804. 

37.   Hu K, Gu Y, Lou L, Liu L, Hu Y, WangB, Luo Y, Shi J, Yu X, Huang H*. Galectin-3mediates bone marrow microenvironment-induced drug resistance in acute leukemiacells via Wnt/β-catenin signaling pathway.J Hematol Oncol. 2015 Jan 27;8(1):1. 

38.   Gorin NC, Labopin M, Piemontese S,Arcese W, Santarone S, Huang H, Meloni G,Ferrara F, Beelen D, Sanz M, Bacigalupo A, Ciceri F, Mailhol A, Nagler A, MohtyM. T-cell-replete haploidentical transplantation versus autologous stem celltransplantation in adult acute leukemia: a matched pair analysis. Haematologica.2015 Apr;100(4):558-64.

39.   Zhu N, Xiao H, Wang LM, Fu S, ZhaoC, Huang H*. Mutations intyrosine kinase and tyrosine phosphatase and their relevance to the targettherapy in hematologic malignancies. Future Oncol. 2015 Feb;11(4):659-73. 

40.   Ruggeri A, Labopin M, Sanz G,Piemontese S, Arcese W, Bacigalupo A, Blaise D, Bosi A, HuangH, Karakasis D, Koc Y, Michallet M, Picardi A, Sanz J,Santarone S, Sengelov H, Sierra J, Vincent L, Volt F, Nagler A, Gluckman E,Ciceri F, Rocha V, Mohty M. Comparison of outcomes after unrelated cord bloodand unmanipulated haploidentical stem cell transplantation in adults with acuteleukemia.Leukemia. 2015.29(9):1891-900.

41.   Wang B, Hu Y, Liu L, Hu K, Tie R, HeY, Fu S, Zhu N, Luo Y, Yu X, Huang H*. Phenotypicaland Functional Characterization of Bone Marrow Mesenchymal Stem Cells inPatients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015.21(6):1020-8. 

42.   Wang X, Wang Y, Wu X, Wang J, Wang Y,Qiu Z, Chang T, Huang H, Lin RJ, YeeJK. Nat Biotechnol. Unbiased detection of off-target cleavage by CRISPR-Cas9and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol. 2015Feb;33(2):175-8.

43.   PiemonteseS, Ciceri F, Labopin M, Bacigalupo A, HuangH, Santarone S, Gorin NC, Koc Y, Wu D, Beelen D, Tischer J, Ehninger G,Arcese W, Nagler A, Mohty M*. A survey on unmanipulated haploidenticalhematopoietic stem cell transplantation in adults with acute leukemia.Leukemia. 2015.29(5):1069-75.

44.   FuS, Wei J, Wang G, Wang B, Wang Y, Lai X, Huang H*. The key role of PML in IFN-α induced cellularsenescence of human mesenchymal stromal cells. Int J Oncol. 2015. 46(1):351-9. 

45.   ZiFM, He JS, Li Y, Wu C, Yang L, Yang Y, Wang LJ, He DH, Zhao Y, Wu WJ, Zheng GF,Han XY, Huang H, Yi Q, Cai Z.Metformin displays anti-myeloma activity and synergistic effect withdexamethasone in vitro and in xenograft models. Cancer Lett. 2015. 356(2 PtB):443-53.

46.   ChenB, Chen X, Wu X, Wang X, Wang Y, Lin TY, Kurata J, Wu J, Vonderfecht S, SunG, Huang H, Yee JK, Hu J, Lin RJ. Disruption of microRNA-21 byTALEN leads to diminished cell transformation and increased expression ofcell-environment interaction genes. Cancer Lett. 2015.356(2 Pt B):506-16.

47.   Wang L, Xiao H, Zhang X, Wang C, Huang H*.The role oftelomeres and telomerase in hematologic malignancies and hematopoietic stemcell transplantation. J Hematol Oncol. 2014Aug 20;7:61. 

48.   Gu M, Zhang T, Lin W, Liu Z, Lai R, Xia D, Huang H , Wang X*.Protein phosphatase PP1 negatively regulates the Toll-like receptor- andRIG-I-like receptor-triggered production of type I interferon by inhibitingIRF3 phosphorylation at serines 396 and 385 in macrophage. Cell Signal. 2014.26(12):2930-9. 

49.   Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W,Zhu Y, Ye X, Yu X, Cai Z, Lin M, HuangH*. T-cell-replete haploidentical HSCT with low-doseanti-T-lymphocyte globulin compared with matched sibling HSCT and unrelatedHSCT.  Blood. 2014. 124(17):2735-43. 

50.   He Y, Wu K, Hu Y, Sheng L, Tie R, Wang B, Huang H*. γδT cell and other immune cells crosstalk in cellular immunity. J Immunol Res. 2014:960252.

51.   Tan Y, Du K, Luo Y, Shi J, Cao L, Zheng Y, Zheng G, ZhaoY, Ye X, Cai Z, Huang H*. Superiorityof preemptive donor lymphocyte infusion based on minimal residual disease in acuteleukemia patients after allogeneic hematopoietic stem cell transplantation.Transfusion. 2014 Jun;54(6):1493-500.

52.   Tie R, Zhang T, FuH, Wang L, Wang Y, He Y, Wang B, Zhu N, Fu S, Lai X, Shi J, Huang H*. Association betweenDNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: asystematic review and meta-analysis. PLoS One. 2014 Jun 17;9(6):e93353.

53.   He J, Yang L, Han X, Zheng G, Zheng W,Wei G, Wu W, Ye X, Shi J, Xie W, Li L, Zhang J, Huang W, Zhao Y, Huang H, Zhang X, Fu J, Cai Z.The choice of regimens based on bortezomib for patients with newly diagnosedmultiple myeloma. PLoS One. 2014 Jun 11;9(6):e99174.

54.   ZiFM, He JS, Li Y, Wu C, Wu WJ, Yang Y, Wang LJ, He DH, Yang L, Zhao Y, Zheng GF,Han XY, Huang H, Yi Q, Cai Z.Fibroblast activation protein protects bortezomib-induced apoptosis in multiplemyeloma cells through β-catenin signaling pathway. Cancer Biol Ther. 2014 Jul21;15(10).

55.   Chen WL, Wang JH, Zhao AH, Xu X,Wang YH, Chen TL, Li JM, Mi JQ, Zhu YM, Liu YF, Wang YY, Jin J, Huang H, Wu DP, Li Y, Yan XJ,Yan JS, Li JY, Wang S, Huang XJ, Wang BS, Chen Z, Chen SJ, Jia W. A distinctglucose metabolism signature of acute myeloid leukemia with prognostic value.Blood. 2014 Sep 4;124(10):1645-54

56.   Wu D, Shao K, Sun J, Zhu F, Ye B, Liu T,Shen Y, Huang H, Zhou Y.Matrine cooperates with all-trans retinoic acid on differentiation induction ofall-trans retinoic acid-resistant acute promyelocytic leukemia Cells (NB4-LR1):possible mechanisms. Planta Med. 2014 Mar;80(5):399-408.

57.   Hu J, Lei Y, Wong WK, Liu S, Lee KC, HeX, You W, Zhou R, Guo JT, Chen X, Peng X, Sun H, Huang H, Zhao H, Feng B. Direct activation of human andmouse Oct4 genes using engineered TALE and Cas9 transcription factors. NucleicAcids Res. 2014 Apr;42(7):4375-90.

58.   Wang X, Wang Y, Huang H, Chen B, Chen X, Hu J,Chang T, Lin RJ, Yee JK. Precise gene modification mediated by TALEN andsingle-stranded oligodeoxynucleotides in human cells. PLoS One. 2014 Apr1;9(4):e93575.

59.   ZhangY, Hu K, Hu Y, Liu L, Wang B, Huang H*.Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect ofgenotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation.Ann Hematol. 2014 Sep;93(9):1499-508.

60.   ZhaoY, Luo Y, Shi J, Cai Z, Huang H*.Second-generation tyrosine kinase inhibitors combined with stem celltransplantation in patients with imatinib-refractory chronic myeloid leukemia.Am J Med Sci. 2014 Jun;347(6):439-45.

61.   Wang Y, Zhao Y, Liu L, Zhang L,Xiao H, Wu K, Xu Y, Hu Y, Fu H, Cao W, Luo Y, Huang H*. Inhibitory effects of imatinib mesylate on humanepidermal melanocytes. Clin Exp Dermatol. 2014 Mar;39(2):202-8.

62.   JiangY, Hu K, Xie W, Zheng G, Sun J, Zheng Y, HuangH*. Hyperthyroidism with  concurrentFMS-like tyrosine kinase 3-internal tandem duplication- positive acute  promyelocytic leukemia: A case report andreview of the literature. Oncol Lett. 2014 Feb;7(2):419-422.

63.   Wu K, Zhao Y, He Y, Wang B, Du K, Fu S, Hu K, Zhang L,Liu L, Hu Y, Wang Y,  Huang H*. Rapamycin interacts synergistically withidarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymalstem cell simulated drug-resistant microenvironment via Akt/mammalian target ofrapamycin and extracellular signal-related kinase signaling pathways.LeukLymphoma.55(3):668-676. 2014.

64.   WuK, Wang Y, He Y, Hu Y, Fu H, Sheng L, Wang B, Fu S,  Huang H*.Dasatinib promotes the potential of proliferation and antitumor responses ofhuman γδT cells in a long-term induction ex vivo environment.Leukemia. 28(1):206-210. 2014.

65.   Gu Y, Hu Y, Hu K, Liao W, Zheng F, Yu X, Huang H*. Rapamycin together with TGF-β1, IL-2 and IL-15 inducesthe generation of functional regulatory γδT cells from human peripheral bloodmononuclear cells. J Immunol Methods. 402(1-2):82-87. 2014.

66.   Xiao H, Luo Y, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W,Ye X, Yu X, Cai Z, Lin M, Huang H*. Donor TLR9 genetagSNPs influencesusceptibility to aGVHD and CMV reactivation in the allo-HSCT setting withoutpolymorphisms in the TLR4 and NOD2 genes. Bone Marrow Transplant. 49(2):241-247.2014.

67.   SunJ, Fu S, Zhong W, Huang H*. PML overexpression inhibitsproliferation and promotes the osteogenic differentiation of human mesenchymalstem cells. Oncol Rep. 30(6):2785-94.2013.

68.   JiangY, Xie W, Hu K, Sun J, Zhu X, Huang H*. An aggressive form of non-Hodgkin'slymphoma with pleural and abdominal chylous effusions: A case report and reviewof the literature. Oncol Lett. 6(4):1120-1122. 2013.

69.   ZhuX, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, Zhang J, Ye X, LinM, Cai Z, Huang H*.Combination of low-dose mycophenolatemofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelateddonor allogeneic stem cell transplantation. Leuk Res . 37(9): 1046-51. 2013.

70.   Sheng L, Fu S, Hu Y, Fu H, Huang H*. Rapid mobilization of fully functional natural killercells into blood by AMD3100. Transfusion. 53(9):2108-1010. 2013.

71.   Hu Y, Cui Q, Gu Y, Sheng L, Wu K, Shi J, Tan Y, Fu H, LiuL, Fu S, Yu X,  Huang H*.Decitabine facilitates the generationand immunosuppressive function of regulatory gammadeltaT cells derived fromhuman peripheral blood mononuclear cells. Leukemia. 27(7): 1580-1585. 2013.

72.   XieW, Zhou D, Hu K, Xiao X, Huang W, He J, Shi J, Luo Y, Zhang J, Lin M, CaiZ, Huang H, Ye X*. Clinical analysis andprognostic significance of hepatitis B virus infections for diffuse largeB-cell lymphoma with or without rituximab therapy. Exp Ther Med. 6(1):109-114.2013.

73.   ZhaoY, Huang H, Wei G*. Novel agents and biomarkers for acute lymphoid leukemia. JHematol Oncol. 6:40. 2013.

74.   Zhang L, Zheng W, Wang Y, Wang Y, Huang H*. Human bonemarrow mesenchymal stem cells support the derivation and propagation of humaninduced pluripotent stem cells in culture. Cell Reprogram. 15(3):216-223. 2013.

75.   Zhou D, Xie W,Hu K, Huang W, Wei G, He J, Shi J, Luo Y, Li L, Zhu J, Zhang J, Lin M, Ye X,Cai Z, Huang H*. Prognostic valuesof various clinical factors and genetic subtypes for diffuse large B-celllymphoma patients: a retrospective analysis of 227 cases. Asian Pac J CancerPrev. 14(2):929-34. 2013.

76.   Du K, Hu Y, Wu K, HuangH*. Long-term outcomes of antithymocyte globulin in patients withhematological malignancies undergoing myeloablative allogeneic hematopoieticcell transplantation: a systematic review and meta-analysis. Clin Transplant.27(2):E91-E100. 2013.

77.   Zheng W, Wang Y, Chang T, Huang H*. and Yee JK*. Significant differencesin genotoxicity induced by retrovirus integration in human T cells and inducedpluripotent stem cells. Gene. 519(1):142-9. 2013.

78.   Xie W, Hu K,Xu F, Zhou D, He J, Shi J, Luo Y, Zhu J, Zhang J, Lin M, Ye X, HuangH, Cai Z*. Clinical analysis and prognostic significance oflymphoma-associated hemophagocytosis in peripheral T cell lymphoma. AnnHematol. 92(4): 481-486. 2013.

79.   ShiJ, Meng X, Luo Y, Tan Y, Zhu X, Zheng G, He J, Zheng WY Xie W, Li L, Ye X,Zhang J, Cai Z, Lin M, Huang H*. Clinical characteristics and outcome of isolated extramedullary relapsein acute leukemia after allogeneic stem cell transplantation: a single-centeranalysis. Leuk Res. 37(4):372-7.2013.

80.   He J, Zhu L, Ye X, Li L, Zhu J, Zhang J, Xie W, Shi J, Zheng W, Wei G, Sun J, CaiZ, HuangH*. Clinical Characteristics and Prognosis of 23 Patients With Nonleukemic Myeloid Sarcoma.Am J Med Sci. 2014 Jun;347(6):434-8.

81.   WangC, Xiao H, Ma J, Zhu Y, Yu J, Sun L, Sun H, Liu Y, Jin C, Huang H*.  The F-box protein beta-TrCP promotesubiquitination of TRF1 and regulates the ALT-associated PML bodies formation inU2OS cells. Biochem Biophys Res Commun.434(4):728-34. 2013.

82.   Xie W, Zhao Y, Cao L, Huang W, Wang Y, Huang H*. Cutaneous blastic plasmacytoid dendritic cellneoplasm occurring after spontaneous remission of acute myeloid leukemia: acase report and review of literature.Med Oncol. 29(4):2417-22. 2012.

83.   Xiao H, Luo Y,Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X,Yu X, Cai Z, Lin M, Huang H*. Genetic variations inT-cell activation and effector pathways modulate alloimmune responses afterallogeneic hematopoietic stem cell transplantation in patients with hematologicmalignancies. Haematologica.97 (12):1804-1812. 2012.

84.   Hu Y, Gu Y,Cui Q, Fu H, Sheng L, Wu K, Liu L, Fu S, Yu X, Huang H*. Phytohemagglutinin -activated human T cells induce lethal graft-versus-host disease incyclophosphamide and anti - CD122 conditioned NOD/SCID mice. Ann Hematol . 91(11): 1803-1822. 2012.

85.   Zhu Y, Wang C,Lan J, Yu J, Jin C. & Huang H*.Phosphorylation of Tara by Plk1 is essential for faithful chromosomesegregation in mitosis. Exp Cell Res. 318 (18), 2344-2352. 2012.

86.   Liu L, Hu K, Wang B, HuangH*Yu, Q. Mobilizationof endogenous stem cells: A new strategy for bone healing. Bone. 51 (3): 633-634. 2012. (IF: 3.823)

87.   Wu W, Cao L, Li Y, Yu X, Huang H, He J*. Primary splenic diffuse large B-cell lymphoma in a patient withthymus Rosai-Dorfman disease. Am J Med Sci. 344(2):155-9. 2012.

88.   Wu K, Luo Y, Liu L, Zhao Y, Hu Y, Tan Y,Lai X , Huang H*. Twinpregnancy and childbirth after reduced-intensity conditioning allogeneichaematopoietic stem cell transplantation combined with imatinib mesylate forchronic myeloid leukaemia: case report and literature review. J Int Med Res .40:2409-15. 2012.

89.   Wang T, Huang HCHTzeng, Wang P, Wu T, Sun J, Tang J, Hu J, Lin S, Kao R*. Impact of donorcharacteristics and HLA matching on survival of chinese patients withhematologic malignancies undergoing unrelated hematopoietic stem celltransplantation. Biol Blood Marrow Transplant .18:1939-44. 2012.

90.   Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J*. Multicenter, randomized,open-label study comparing the efficacy and safety of micafungin versusitraconazole for prophylaxis of invasive fungal infections in patientsundergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant18:1509-16. 2012.

91.   Xu Y, Liu L, Zhang L, Fu S, Hu Y, Wang Y, Fu H, Wu K, Xiao H,Liu S, Yu X, Zheng W, Feng B, Huang H*.Efficient commitment tofunctional CD34+ progenitor cells from human bone marrow mesenchymalstem-cell-derived induced pluripotent stem cells. PLoS One 7(4): e34321. 2012.

92.   ZhangL, Wang Y, Huang H*. Defibrotidefor the prevention of hepatic veno-occlusive disease after hematopoietic stemcell transplantation: a systematic review.Clin Transplant.26 (4): 511-519. 2012.

93.   SunJ, Wang Z, Luo Y, Tan Y, David S.Allan, HuangH*.Prolongedsurvival with imatinib mesylate combined with chemotherapy and allogeneic stemcell transplantation in de novo Ph+ acute myeloid leukemia. Acta Haematol.127:143-148. 2012.

94.   XuY, Liu L, Zhang L, Fu S, Li R, Hu K and HuangH*.Efficientgeneration of induced pluripotent stem cells from human bone marrow mesenchymalstem cells. Folia Biol (Praha) . 58(6):221-30. 2012.

95.   Cao W, Xiao H, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, XieW, Li L, Ye X, Yu X, Lin M, Cai Z,Huang H*. Geneticvariations in the mycophenolate mofetil target enzyme are associated with acuteGVHD risk after related and unrelated hematopoietic cell transplantation. BiolBlood Marrow Transplant. 18(2): 273-279. 2012.

96.   HuY, LuoY, Tan Y, Shi J, Sheng L, Fu H, Liu L, Xu Y, Wu K, Xiao H, Zhang L, Yu X,Cai Z, HuangH*Donor bone marrow-derived stem cells contribute tooral squamous cell carcinoma transformation in a recipient after hematopoieticstem cell transplantation. Stem Cells Dev. 21: 177-180. 2012.

97.   ChangT, Zheng W, Tsark W, Bates S, Huang H, Lin R, Yee JK*.  Phenotypicrescue of Induced pluripotent stem cell-derived motoneurons of a spinalmuscular atrophy patient. Stem Cells. 29: 2090-2093. 2011.

98.   Wei G, Ni W, Chiao J, Cai Z, Huang H Liu D*. Ameta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for thetreatment of 1029 patients with acute myeloid leukemia and myelodysplasticsyndrome. J Hematol Oncol, 4: 46. 2011.

99.   Liu L, Wang Y, Wu K, Fu S, Zhang L, Xu Y, Huang H*. The tyrosine kinaseinhibitor nilotinib inhibits proliferation and osteoblast differentiation ofhuman mesenchymal stromal cells. Bone. 49(5):1117-1118. 2011.

100.  Liu L, Yu Q, Lin J, Lai X, Cao W, Du K, Wang Y, Wu K, Hu Y,Zhang L, Xiao H, Duan Y, Huang H*. Hypoxia-induciblefactor-1α is essential for hypoxia-induced mesenchymal stem cell mobilizationinto the peripheral blood. Stem Cells Dev. 20(11):1961-71. 2011.

101.  LuoY, Zhao Y, Tan Y, Shi J, Han X, Zheng Y, Li L, He J, Xie W, Ye X, Cai Z, Lin M,Huang H*. Imatinib combined with myeloablativeallogeneic hematopoietic stem cell transplantation for advanced phases ofchronic myeloid leukemia. Leu Res. 35: 1307-1311. 2011.

102.  Zhao Y, Tan Y, Wu G, Liu L, Wang Y, Luo Y, Shi J, Huang H*.Berbamine overcomes imatinib-induced neutropenia and permits cytogeneticresponses in Chinese patients with chronic-phase chronic myeloid leukemia. Int J Hematol. 94:156-162. 2011.

103.  Hu Y, Cui Q, Liang B,HuangH* Relapsing hematologic malignancies afterhaploidentical hematopoietic stem cell transplantation. Biol Blood MarrowTransplant. 17(8): 1099-1111.2011.

104.  Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W,Zhang L, Wang Y, Liu L, Wu K, Yu X, Cai Z, Lin M, Ye X, Huang H*.First report of multiple CEBPA mutationscontributing to donor origin of leukemia relapse after allogeneic hematopoieticstem cell transplantation. Blood. 117(19): 5257-5260. 2011.

105.   Tan Y, Fu H, LuoY, Shi J, Ye X, ZhengY, Xiao H, Hu Y, Huang H*..Haploidentical Allogeneic Haematopoietic Stem Cell Transplantation asSalvage Therapy for Engraftment Failure after Unrelated and Autologous StemCell Transplantation: a Case Report and Review of the Literature. J IntMed Res. 39: 950-959. 2011.

106.   XiaoH, Cao W, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng W, Zheng G,Han X, Jin L, Zhang L, Wang Y, Yu X, Cai Z, Lin M, Ye X, HuangH*.Immunosuppressive cytokine gene polymorphisms and outcome after related andunrelated hematopoietic cell transplantation in Chinese population. Biol BloodMarrow Transplant. 17: 542-549. 2011.

107.   XiaoH, Lai X, LuoY, Shi J, Tan Y, He J, Xie W, Li L, Zhu X, Zhu J, Sun J, Wei GJin LLiu LWu KYu X, Cai Z, Lin M, Ye X, Huang H*. Relationship between TNFA, TNFB andTNFRII gene polymorphisms and outcome after unrelated hematopoietic celltransplantation in Chinese population. Bone Marrow Transplant. 46: 400-407.2011.

108.   MouH, Lin M, Huang H, Cai Z*.Transforming growth factor-beta1 modulates lipopolysaccharide-inducedcytokine/chemokine production and inhibits nuclear factor-kappaB, extracellularsignal-regulated kinases and p38 activation in dendritic cells in mice.Transplant Proc. 2011. 43(5):2049-2052.

109.   WangC, Yu J, Yuan K, Lan J, Jin C*, Huang H*.  Plk1-mediated phosphorylation of PinX1regulates its stability. Eur J Cell Biol. 89(10): 748-756. 2010.

110.   Hu Y, Cui Q, Liang B, HuangH*. Donor-derivedsolid malignancies after hematopoietic stem cell transplantation. Onkologie.33(4):195-200. 2010.

111.   Wu G,Zhao Y, Lai X, Luo Y, Tan Y, Shi J, Li L, Zheng W, Zhang J, Hu X, Jin A, He J,Xie W, Ye X, Cai Z, Lin M, Huang H*. The beneficialimpact of missing KIR ligands and absence of donor KIR2DS3 gene on outcomefollowing unrelated hematopoietic SCT for myeloid leukemia in the Chinesepopulation. Bone Marrow Transplant. 45: 1514-1521. 2010.

112.   ZhengW, Guan M, Zhu L, Cai Z, Chung V, Huang H* YenY. Bortezomib therapeutic effect is associated with expression and mutation ofFGFR3 in human lymphoma cells. Anticancer Res. 30(6): 1921-1930. 2010.

113.   Dong-WookKim*, Shripad D. Banavali, Udomsak Bunworasate, Yeow-Tee Goh, Peter Ganly, Huang H, Ian Irving, Saengsuree Jootar, Hyun-GyungGoh, Liang-Piu Koh, Wei Li, Tomoki Naoe, Soo-Chin Ng, Visalachy Purushotaman,Harryanto Reksodiputro, Lee-Yung Shih, Jih-Luh Tang, Arinobu Tojo, JianminWang, Raymond Wong. Chronic myeloid leukemia in the Asia-Pacific region:current practice, challenges and opportunities in the targeted therapy era.Leuk Res. 34(11): 1459-1471. 2010.

114.   Yu J,Lan J, Wang C, Wu Q, Zhu Y, Lai X, Sun J, Jin C*, HuangH*. PML3 interacts with TRF1 and is essential forALT-associated PML bodies assembly in U2OS cells. Cancer Lett. 291(2): 177-186.2010.

115.   Wu G,Zhao Y, Lai X, Yang K, Zhu F, Zhang W, Wang W, Luo Y, Tan Y, Wang Y, Cao W, Huang H*.Distribution of killer-cell immunoglobulin-like receptor genes in Easternmainland Chinese Han and Taiwanese Han populations. Tissue Antigens. 74(6):499-507. 2009.

116.   Wu Q,Hu H, Lan J, Emenari C, Wang Z, Chang K, HuangH, Yao X*. PML3 Orchestrates the Nuclear Dynamics andFunction of TIP60. J Biol Chem. 284(13):8747-8759. 2009.

117.   LuoY, Lai X, Tan Y, Shi J, Zhao Y, Han X, Zheng G, Zhu X, Sun J, Zheng Y, Wu G, HeJ, Chen S, Jin A, Xie W, Ye X, Cai Z, Lin M, HuangH*.Reduced-intensity allogeneic transplantation combined with imatinib mesylatefor chronic myeloid leukemia in first chronic phase. Leukemia. 23(6):1171-1174.2009.

118.   ZhaoY, Liu L, Wang Y, Wu G, Lai X, Cao W, Luo Y, Tan Y, Shi J, Xie W, Ye X, Cai Z,Lin M, Huang H*. Efficacy and Prognosis of Chronic Myeloid Leukemia TreatedWith Imatinib Mesylate in a Chinese Population. Int J Hematol.89(4):445-451. 2009.

119.   ZhaoY, Wu G, Wu K, Liu L, Cao W, Yu X, Luo Y, Shi J, Tan Y, Huang H*.  Simultaneousoccurrence of variant Philadelphia translocations and ABL mutations in twopatients with chronic myeloid leukemia. Leuk Res. 33(7):e85-87. 2009.

120.   ZhengW, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X,Lin M, Huang H, CaiZ*. Bortezomib in combination withdexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma:a Chinese experience. Leuk Res. 33(12):1615-1618. 2009.

121.   QiuL, He J*, Ye X, Xie W, Shi J, Zheng W, Sun J, Zhu X, Cai Z, Huang H, Lin M. Invasive pulmonary fungalinfection accompanied by severe hemoptysis in patients with hematologicdiseases: a report of nine cases. Int J Hematol. 90(1):108-112. 2009.

122.   ShiJ, Cai Z*, Huang H, YeX, He J, Xie W, Zhang J, Zhou X, Luo Y, Lin Y, Li L, Zheng W, Wei G, Lin M.Role of CT-guided percutaneous lung biopsy in diagnosis of pulmonary fungalinfection in patients with hematologic diseases. Int J Hematol. 89(5):624-627.2009.

123.   Yu J,Lan J, Zhu Y, Li X, Lai X, Xue Y, Jin C*, HuangH*. The E3 ubiquitin ligase HECTD3 regulates ubiquitination anddegradation of Tara. Biochem Biophys ResCommun. 367(4):805-812. Mar 2008. 

124.   ZhaoYM, Li JY, Lan JP, Lai XY, Luo Y, Sun J, Yu J, Zhu YY, Zeng FF, Zhou Q, Huang H*. Cell cycle dependenttelomere regulation by telomerase in human bone marrow mesenchymal stem cells.Biochem Biophys Res Commun. 369(4): 1114-1119. May 2008. 

125.   ZhaoYM, Zhou Q, Xu Y, Lai XY, Huang H*.Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkatby cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin. 29(4):481-488. Apr 2008.

126.   ChengZ, Ke Y, Ding X, Wang F, Wang H, Wang W, Ahmed K, Liu Z, Xu Y, Aikhionbare F,Yan H, Liu J, Xue Y, Yu J, Powell M, Liang S, Wu Q, Reddy SE, Hu R, Huang H, Jin C, Yao X*.Functional characterization of TIP60 sumoylation in UV-irradiated DNA damageresponse. Oncogene. 27(7): 931-941. Feb 2008.

127.   LuoY, Zhang A, Huang H*, ZhengS. Haemolytic uraemic syndrome after living-donor liver transplantationis small-for-size graft a potential riskfactor J Int Med Res. 36(3):599-604. May-Jun 2008.

128.   Li X,Lan J, Zhu Y, Yu J, Dou Z, Huang H*.Expression, purification, and characterization of Tara,a novel telomere repeat-binding factor 1 (TRF1)-binding protein. Protein ExprPurif. 55(1):84-92. Sep 2007.

129.   SunJ, Huang H*, Zhu Y, Lan J, LiJ, Lai X, Yu J. The expression of telomeric proteins and their probableregulation of telomerase during the differentiation of all-trans-retinoicacid-responsive and -resistant acute promyelocytic leukemia cells. Int J Hematol. 82(3):215-222. Oct 2005.

130.    Fu C,Ahmed K, Ding H, Ding X, Lan J, Yang Z, Miao Y, Zhu Y, Shi Y, Zhu J, Huang H*, Yao X*. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.Oncogene. 24(35): 5401-5413. Aug 2005.

 

发表著作:

1.  周晋,黄河(主编). 2009.《血液内科学》第一版,第二版,人民卫生出版社

2.  黄河(副主编).2009.2010西医综合考试辅导与模拟试题》,浙江大学出版社.

3.  黄河(参编).2009.《内科学新进展》,浙江大学出版社

4.  黄河(副主编).2003.《临床疾病与免疫》,科学出版社

5.  黄河(参编).2002.《感染微生态学》,人民卫生出版社

 

发明专利:

1.  抗人骨髓间充质干细胞单克隆抗体ZUF10及应用,专利号:ZL 2005 1 0061032.3; (排名第一)

2.  抗人骨髓间充质干细胞单克隆抗体ZUC3及应用,专利号:ZL 2005 1 0061033.8; (排名第一)

3.  抗人骨髓间充质干细胞单克隆抗体ZUB1及应用,专利号:ZL 2005 1 0061034.2; (排名第一)

4.  抗人骨髓间充质干细胞单克隆抗体ZUE12及应用,专利号:ZL 2005 10061035.7; (排名第一)

5.  抗人骨髓间充质干细胞单克隆抗体ZUB4及应用,专利号:ZL 2005 1 0061036.1; (排名第一)

6.  单抗ZUE12免疫磁珠分选人骨髓间充质干细胞的方法,专利号:ZL 2006 1 0050759.6;(排名第一)

7.  单抗ZUB1免疫磁珠分选原代人骨髓间充质干细胞的方法,专利号: ZL200610050760.9;(排名第一)

8.  单抗ZUC3免疫磁珠分选原代人骨髓间充质干细胞的方法,专利号:ZL 2006 1 0050761.3;(排名第一)

9.  单抗ZUB4免疫磁珠分选原代人骨髓间充质干细胞的方法,专利号:ZL 2006 1 0050762.8;(排名第一)

10. 单抗ZUF10免疫磁珠分选人骨髓间充质干细胞的方法,专利号:ZL 2006 1 0050763.2;(排名第一)

11. 一种获得诱导多能干细胞的方法,专利号:ZL201110261281.2;(排名第一)

12. 一种获得造血干细胞的方法,专利号:ZL201110300957.4;(排名第一)

13. 一种NOD/SCID小鼠异种移植物抗宿主病模型的建立方法,专利号:201210005931.1;(排名第一)

14. 一种调节性T细胞的诱导培养方法,专利号:ZL201110035687.9;(排名第一)

15. 用人间充质干细胞滋养层培养诱导多能干细胞的方法,专利号:ZL201110036898.4;(排名第一)

16. 雷帕霉素诱导调节性γδT细胞的培养方法,专利号:ZL201310384046.3;(排名第一)

17. IDLV为模板的TALEN靶向基因编辑优化方法,专利号: ZL201410059599.6;(排名第一)

 

在国际大型会议担任主席、特邀报告和口头报告:

       Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Zhu Y, Ye X, Cai Z, Lin M and Huang H*. Prospective evaluation of T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with contemporaneous matched sibling HSCT and unrelated HSCT: results from an open-label trial. 40届欧洲血液与骨髓移植年会, 2014.3.30-4.2, Milan, Italy, 口头报告

       Xiao H, Huang H*. Genomic Evolution and Genetic Alterations in Adult Patients with Philadephia Chromosome-negative Acute Lymphoblastic Leukemia from Diagnosis to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. 40届欧洲血液与骨髓移植年会, 2014.3.30-4.2, Milan, Italy, 口头报告

       Wang Y, Zhang L, Liu S, Huang H*. Defining Molecular Roadblocks through an Intermediate Standstill Derived during Reprogramming Human Fibroblast to iPS Cell. 40届欧洲血液与骨髓移植年会, 2014.3.30-4.2, Milan, Italy, 口头报告

       Hu K, Gu Y, Lou L, Liu L, Hu Y, Fu S, Wang B, Yu X, Huang H*. Bone marrow mesenchymal stromal cells protect acute leukemia cells from cytotoxic agents via galectin-3 mediated Wnt/β-catenin signaling. 40届欧洲血液与骨髓移植年会, 2014.3.30-4.2, Milan, Italy, 口头报告

       Xiao H, Luo Y, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Fu S, Wang Y, Ye X, Yu X, Cai Z, and Huang H*. Whole-exome Sequencing of Adult Philadephia-negative Acute Lymphoblastic Leukemia from Diagnosis to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Reveals Clonal Evolution and Relapse-associated Mutated Genes. 55届美国血液学年会, 2013.12.7-10, Blood 2013 122:156, New Orleans, USA, 口头报告

       Zhang M, Luo Y, Lai X, Tan Y, Zheng W, Zhu Y, Shi J, and Huang H*. Minimal residual disease levels at time of CR1 and transplant predict outcome in Philadephia chromosome-negative adult ALL. 55届美国血液学年会, 2013.12.7-10, Blood 2013 122:713, New Orleans, USA, 口头报告

       Huang H*. Biology, Prevention and Treatment of Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. 18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 特邀报告

       Du K, Huang H*. A signal center analysis of Philadephia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in imatinib era. 18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 口头报告

       Shi J, Huang H*. Epidemiology of invasive fungal infections in allogeneic stem cell transplantation recipients: risk factors for infection according to time after transplantation. 18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 口头报告

       Hu Y, Huang H*. Reduced frequency of FOXP3+ gammadeta TCR+ regulatory T cells in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 口头报告

       Tan Y, Huang H*.Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients post allogeneic hematopoietic stem cell transplantation. 18届亚太地区骨髓移植会议, 2013.11.1-4, Ho Chi Ming City, Vietnam, 口头报告

       Hu Y, Luo Y, Shi J, Tan Y, Zheng W, Cai Z, Huang H*.HBsAg- recipients had comparable outcomes and acquired HBV-specific humoral immunity after haematopoietic stem cell transplantation from HBsAg+ donors. Bone Marrow Transplant. 48(suppl 2): S29.39届欧洲血液与骨髓移植年会, 2013.4.7-10, London, UK, 口头报告

       Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, ZhangL, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*.Genetic variations in graft-versus-leukemia reaction pathways and relapse risk after allogeneic hematopoietic stem cell Transplantation: an explore study. 美国国立卫生研究院第二届国际造血干细胞移植后复发工作会议, 2012.11.5-6, Washington, USA, 口头报告

       Huang H*. Allogeneic transplantation in AML-CR1 in era of molecular markers. 17届亚太地区骨髓移植会议, 2012.10.26-28, Hyderabad, India, 特邀报告

       Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*Genetic variations in Toll-like receptors and acute GVHD in allogeneic hematopoietic stem cell transplantation. 17届亚太地区骨髓移植会议, 2012.10.26-28, Hyderabad, India, 口头报告

       Hu Y, Gu Y, Wu K, Sheng L, Huang H*.Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice. 17届亚太地区骨髓移植会议, 2012.10.26-28, Hyderabad, India, 口头报告

       Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*. Persistent cytomegalovirus reactivation and cytomegalovirus UL97 mutations in the seropositive haematopoietic stem cell transplantation setting. Bone Marrow Transplant. 47(suppl 2): S25.38届欧洲血液与骨髓移植年会, 2012.4.1-4, Geneva, Switzerland, 口头报告

       Hu Y, Gu Y, Sheng L, Wu K, Shi J, Tan Y, Yu X, and Huang H *. Decitabine -conditioned regulatory gamma delta T Cells provide enhanced protection from graft-versus-host disease via improved Foxp3 stability and ICOS up-regulation. Bone Marrow Transplant. 47(suppl 2): S72. 38届欧洲血液与骨髓移植年会, 2012.4.1-4, Geneva, Switzerland, 口头报告

       Wu KN, Hu YX, Fu HR, Sheng LX, and Huang H*. Ex Vivo-Expanded gamma&delta-T Cells Can Efficiently Kill Human Acute Myeloid Leukemia Cells Via Trogocytosis. 53届美国血液学年会, 2011.12.10-13, Blood 2011; 118: 580, San Diego, USA, 口头报告

      Huang H*. Biological advances and intervention in leukemia relapse following allogeneic hematopoietic stem cell transplantation. 16届亚太地区骨髓移植会议, 2011.10.30-11.2, Sydney, Australia, 特邀报告

       Xiao H, Luo Y, Shi J, Tan Y, He J, Xie W, Lai X, Yu X, Cai Z, Lin M, Ye X,

Huang H*.Donor Natural Killer Cell Activating Gene Polymorphisms Associated with the Risk of Early Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.16届亚太地区骨髓移植会议, 2011.10.30-11.2, Sydney, Australia, 口头报告

       Huang H*. Plasma Proteins: New Biomarkers in the Diagnosis and Treatment of   Complications of Allogeneic Hematopoietic Stem Cell Transplantat. 7届中日生命科学研讨会, 2011.11.23-24, Kumamoto, Japan, 特邀报告

       Induction of Hematopoietic Commitment from Adult Human Bone Marrow Mesenchymal Stem Cell-derived Induced Pluripotent Stem Cells with Cytokines. 16届亚太地区骨髓移植会议, 2011.10.30-11.2, Sydney, Australia, 口头报告

       Xiao H, Luo Y, Shi J, Tan Y, He J, Xie W, Lai X, Yu X, Cai Z, Lin M, Ye X,

Huang H*.Donor selection for natural killer cell activating genes leads to a reduced rate of relapse after allogeneic hematopoietic cell transplantation both for acute myeloid leukemia and acute lymphoblastic leukemia. Bone Marrow Transplant. 46(suppl 2): S73.37届欧洲血液与骨髓移植年会, 2011.4.3-6, Paris, France, 口头报告

       Xiao H, Luo Y, Shi J, Tan Y, He J, Xie W, Lai X, Yu X, Cai Z, Lin M, Ye X,

Huang H*.Association between genetic variants in T-cell costimulatory molecule and outcome after unrelated hematopoietic cell transplantation.Bone Marrow Transplant. 46(suppl 2): S18.37届欧洲血液与骨髓移植年会, 2011.4.3-6, Paris, France, 口头报告

       Xiao H, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Zhang L, Wang Y, Cai Z, Lin M,

Ye X, and Huang H*.T-cell costimulatory molecule genotypes are associated with the risk of early cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. 2011年美国血液学会骨髓移植年会, 2011.2.17-21, Honolulu, USA, 口头报告

       Xiao H, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Zhang L, Wang Y, Cai Z, Lin M, Ye X, and Huang H*. The Genotype of T-cell Costimulatory Molecule is Associated with Relapse Incidence in Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. 52届美国血液学年会, 2010.12.4-7, Blood 2010; 116: 684, Orlando, USA, 口头报告

       Huang H*. Recent advances and choices of transplantation conditioning regimen.15届亚太地区骨髓移植会议, 2010.10.28-31, Phuket, Thailand, 主席, 特邀报告

       Xiao H, Zhu X, Cao W, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Zhang L, Wang

Y, Cai Z, Lin M, Ye X, and Huang H*. Effect of low-dose, short-course mycophenolate mofetil as GVHD prophylaxis and study of the polymorphisms of target gene of mycophenolate mofetil.15届亚太地区骨髓移植会议, 2010.10.28-31, Phuket, Thailand, 口头报告, 口头报告二等奖

       Xiao H, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng G, Han X, Yu X,Cai Z, Lin M, Ye X, Huang H*.Donor and recipient TGF-beta 1 gene polymorphisms are associated with the risk of early cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 45(suppl 2): S37.36届欧洲血液与骨髓移植年会, 2010.3.21-24, Vienna, Austria, 口头报告

       Huang H*. New advances in the research of graft-versus-host disease after allo-HSCT. 2010年台湾血液学年会, 2010.4.9, Taiwan, 特邀报告

       Huang H*. Cross-Straits Summit in Managing Acute Leukemia: Challenges and Options in 2010 and Beyond. 2010年台湾血液学年会, 2010.4.9, Taiwan, 主席

       Huang H*. Reduced intensity transplantation: current role and future prospects. 第一届东亚血液学联盟会议, 2010.4.22-24, Kuala Lumpur, Malaysi, 特邀报告

       Huang H*. Transplantation in autoimmune disease. 第一届东亚血液学联盟会议, 2010.4.22-24, Kuala Lumpur, Malaysi, 特邀报告

       Huang H*. China consensus of CML treatment 2010. 2010年亚太慢性粒细胞白血病顾问委员会会议, 2010.4.25, Kuala Lumpur, Malaysi, 特邀报告

       Huang H*. Advance of mesenchymal stem cell research and application in clinic.4届西澳分子与细胞治疗论坛, 2010.4.26-5.7, The University of Western Australia, 特邀报告

       Huang H*. Prophylaxis and treatment of graft-versus-host disease following allo-HSCT. 14届亚太地区骨髓移植会议, 2009.8.27-29, Seoul, Korea, 主席, 特邀报告

       Xiao H, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng G, Han X, Yu X, Cai Z, Lin M, Ye X, Huang H*Association between tumor necrosis factor-α gene polymorphisms and acute graft-versus-host disease in unrelated donor allogeneic haematopoietic stem cell transplantation in Chinese population. 14届亚太地区骨髓移植会议, 2009.8.27-29, Seoul, Korea, 口头报告

       Lai X, Huang H*, Huang L, Cao J, Zeng F, Zheng J. Identification and enrichment of human bone marrow derived mesenchymal stem cells by monoclonal antibody, ZUC3. Bone Marrow Transplant. 41(suppl.1):S16. 34届欧洲血液与骨髓移植年会, 2008.3, Flroence, Italy, 口头报告

       Huang H*, Fan J, Lai X, Yu Q, Ding W, Wang Y. Intracerebral transplantation of human mesenchymal stem cells after hypoxic-ischemic brain damage in rat. 34届欧洲血液与骨髓移植年会, 2008.3, Flroence, Italy, 口头报告

       Huang H*. Allogeneic Transplantation for Acute Lymphoblastic Leukemia. 2007年美国血液肿瘤治疗进展研讨会, New York, USA, 特邀报告

       Huang H*. Treatment Strategies for Adult Acute Lymphoblastic Leukemia: Unrelated Donor Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in First Complete Remission. 12届亚太地区骨髓移植会议, 2007.9, Beijing, China, 特邀报告

       Huang H*. Unrelated Donor Hematopoietic Stem Cell Transplantation for 128 Patients with Hematological Malignancy. 11届亚太地区骨髓移植会议, 2006.10, Nagoya, Japan, 口头报告

       Huang H*. Unrelated Donor Hematopoietic Stem Cell Transplantation for Leukemia and Myelodysplastic Syndrome. 2006年亚太骨髓捐献者登记组织会议, 2006.4, Taiwan, 特邀报告

       Huang H*. Unrelated Donor Hematopoietic Stem Cell Transplantation for Leukemia and Myelodysplastic Syndrome. 10届亚太地区骨髓移植会议, 2005.10, Hangzhou, China, 特邀报告